Name | Department | Grad. | Thesis Topic/Interest | Position |
| Alan Afuah | Sloan School | 1995 | Strategic management of pharmaceutical R&D | Univ. of Michigan |
| Frank Basa | Sloan School | 1995 | Pharmaceutical industry project | management consulting |
| Linda Bui | Economics | 1993 | Measuring health outcomes-adjusted pharmaceutical price changes | Boston Univ. Dept. of Economics |
| Bart Clarysse | Sloan School | 1996 | Pharmaceutical industry structure | academic position in Belgium |
| Gillian Currie | Economics (Yale) | 1998 | Economics of antidepressant medicines | |
| Rebecca D'Amato | Operations Research | 1998 | Outcomes research | |
| Christopher Dowd | Chemical Engineering | 1997 | Growth factor transport through basement membrane | |
| Morten Engel | Chemical Engineering | 1999 | Benchmarking the manufacture of pharmaceuticals | |
| Varghese George | Sloan School | 1996 | Interfirm relationships in the pharmaceutical industry | Rutgers Univ. |
| Arni Hauksson | Operations Research | 1997 | Outcomes research | |
| Charles King III | Economics | 1997 | Economics of the anti-ulcer drug market | Harvard Business School |
| John Konz | Chemical Engineering | 1998 | Effects of oxygen on recombinant protein expression | |
| Kornelia Krajnyak | Economics | 1997 | Pharmaceutical industry structure | International Monetary Fund |
| Michael Laska | Chemical Engineering | 2000 | Benchmarking the manufacture of pharmaceuticals | |
| Per Lindell | Chemical Engineering | 1992 | Strategic issues in pharmaceutical manufacturing | Boston Consulting Group |
| Gerald Lumer | Economics | 1995 | Risk and return in pharmaceutical R&D | U.S. Dept. of Justice |
| Michael Miller | Operations Research | 1996 | Reexamining drug trials | consulting |
| Mark Moore | Economics | 1997 | Economics of industrial organization | |
| Kaivan Munshi | Economics | 1995 | Investment behavior and financial structure | Boston Univ. Dept. of Economics |
| Gil Preuss | Sloan School | 1997 | Human resource incentives and physicians' prescribing behavior | |
| G.K. Raju | Chemical Engineering | 1997 | Early involvement of FDA advisory committees to speed up the drug evaluation process | MIT/CAMP |
| David Reily | Economics | 1996 | The economics of a new industry: the diffusion of modern anti-ulcer drugs | Vanderbilt Univ. Dept. of Marketing |
| Daniel Rodriguez | Economics | 1997 | Economies of scale in the pharmaceutical industry | |
| Fiona Scott Morton | Economics | 1994 | Barriers to entry, brand advertising, and generic entry in U.S. pharmaceutical industry | Stanford Univ. Grad. School of Business |
| Christoper Voisey | Sloan School | 1998 | Pharmaceutical R&D in the new environment | |
| Stefan Weissflog | Chemical Engineering | 1997 | Benchmarking the manufacture of pharmaceuticals | academic position in Germany |
| R. Steven White | Sloan School | 1998 | Pharmaceutical R&D project management |
Name | Department | Degree | Thesis Topic/Interest |
| Adi Alon | Sloan School | MS | Pioneering in the pharmaceutical industry |
| Tetsuya Araki | Sloan School | MS | Japan's pharmaceutical industry: Transformation in response to recent environmental change |
| Peter Bittinger | Sloan School | MS | The effects of price and profit regulation on the international competitiveness of the pharmaceutical industry |
| Gary Brackenridge | Sloan School | BS | Public-private interaction in pharmaceutical research |
| Sean Campbell | Sloan School | MS | Benchmarking the manufacture of pharmaceuticals |
| Thomas Flanagan | Sloan School | MS | Management of clinical research |
| Roland Franke | Sloan School | MS | The role of combinatorial chemistry in drug development |
| Christopher Howe | Sloan School | MBA | Financial modeling of drug R&D |
| Pai-Feng Paul Hsu | Sloan School | MS | On the measurement of price-quality relationships in anti-hypertensive drugs using hedonic price analysis: A feasibility study |
| Shehla Imran | Economics | BS | Economies of scale in the pharmaceutical industry |
| Tim Kaps | Sloan School | MS | Managing and organizing for higher performance in drug development projects |
| Zhara Kherani | Economics | BS | Intellectual property issues in biotechnology |
| Jong Kim | Economics | BS | Generic entry and competition in the pharmaceutical industry |
| Peter Latham | Sloan School | MS | Benchmarking the manufacture of pharmaceuticals |
| Steven Lipari | Sloan School | MS | A medical device as a new business opportunity |
| Michele Lombardi | Electrical Engineering and Computer Science | BS | Marketing issues for anti-ulcer therapy |
| Christophe Malaterre | Technology & Policy | MS | An economic development strategy for the biotechnology industry in Massachusetts |
| Andrew McCraith | Mechanical Engineering | BS | Economies of scale in the pharmaceutical industry |
| Eyal Meltzer | Management of Technology | MS | The order of entry of a drug and market share |
| Christine Moore | Chemical Engineering | MS | Strategic issues in pharmaceutical manufacturing |
| Albert Morales | Sloan School | MS | Benchmarking pharmaceutical manufacturing |
| Jose Pacheco | Economics | BS | Quality adjusted pharmaceutical price indexes |
| Helen Park | Biology | BS | Intellectual property issues |
| Andria Pomponi | Chemistry | BS | Barriers to entry, brand advertising, and generic entry in the U.S. pharmaceutical industry |
| Lisa Prosser | Sloan School | MS | The effect of increased competition on human resource strategies in pharmaceutical R&D |
| Paolo Radaelli | Management of Technology | MS | Strategic alliances among pharmaceutical firms |
| Jordan Rubenson | Sloan School | MS | The emerging strategic role of manufacturing in the pharmaceutical industry |
| Bonnie Scouler | Sloan School | MS | A segmentation analysis of the ulcer drug market |
| John Swen | Sloan School | MS | Use of IT by start-up biotechnology firms |
| Francois Thomas | Sloan School | MS | Outsourcing research in the pharmaceutical industry |
| Matt Verlinden | Sloan School | MS | The effect on isolation technology on aseptic pharmaceutical processing technology |
| Jeffrey Williams | Sloan School | MS | Benchmarking manufacturing costs in the biotechnology industry |
| Hyun-Sook Woo | Sloan School | MS | The effect of project management structure on new drug development |
Please send comments and suggestions to popi-www@mit.edu